Background Regulatory guidance specifies the need to establish cardiovascular safety of
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …

Background It is unknown whether screening for atrial fibrillation and subsequent treatment
with anticoagulants if atrial fibrillation is detected can prevent stroke. Continuous …

To identify genetic variation underlying atrial fibrillation, the most common cardiac arrhythmia,
we performed a genome-wide association study of >1,000,000 people, including 60,620 …

Background— Studies have suggested a link between risk factors for atherosclerotic disease
and venous thromboembolism (VTE), but results are heterogeneous. We sought to identify …

OBJECTIVE To compare the efficacy and safety of once-weekly semaglutide 1.0 mg sc with
exenatide extended release (ER) 2.0 mg sc in subjects with type 2 diabetes. RESEARCH …

Aims Exercise increases risk of ventricular arrhythmia in subjects with arrhythmogenic right
ventricular cardiomyopathy ( ARVC ). We aimed to investigate the impact of exercise on …

Aims To determine the prevalence, predictors of newly acquired, and the prognostic value
of right bundle branch block (RBBB) and incomplete RBBB (IRBBB) on a resting 12-lead …

Background— Atrial fibrillation (AF) affects >30 million individuals worldwide and is associated
with an increased risk of stroke, heart failure, and death. AF is highly heritable, yet the …

Background Results on the association between P-wave duration and the risk of atrial
fibrillation (AF) are conflicting. Objective The purpose of this study was to obtain a detailed …

Cardiomyopathies are a heterogeneous group of diseases with various etiologies. We
focused on three genetically determined cardiomyopathies: hypertrophic (HCM), dilated (DCM), …